SEARCH

SEARCH BY CITATION

References

  • 1
    Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989; 43: 10726.
  • 2
    Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 1994; 106: 35361.
  • 3
    Finn OJ, Jerome KR, Henderson RA et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995; 145: 6189.
  • 4
    Wesseling J, Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7: 56577.
  • 5
    Kemenade EW, Ligtenberg MJL, Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte–target cell interaction. J Immunol 1993; 151: 76776.
  • 6
    Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immmortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993; 151: 165462.
  • 7
    Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161: 58994.
  • 8
    Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18: 57483.
  • 9
    Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003; 103: 97100.
  • 10
    Lloyd KO, Burchell J, Kudryashov V, Yin BWT, Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. J Biol Chem 1996; 271: 33 325–34.
  • 11
    Hanisch FG, Müller S, Hassan H et al. Dynamic epigenetic regulation of initial O-glycosylation by UDP-N-acetylgalactosamine: Peptide N-acetylgalactosaminyltransferases. J Biol Chem 1999; 274: 994654.
  • 12
    Onitsuka K, Shibata K, Nakayama Y et al. Prognostic significance of UDP-N-acetyl-α-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma. Cancer Sci 2003; 94: 326.
  • 13
    Vlad AM, Muller S, Cudic M et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: Processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002; 196: 143546.
  • 14
    Snijdewint FGM, Von Mensdorff-Pouilly S, Karuntu-Wanamarta AH et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001; 93: 97106.
  • 15
    Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18: 20316.
  • 16
    Stahel RA, Gilks WR, Lehmann HP, Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer Suppl 1994; 8: 626.
  • 17
    Kohno N, Kyoizumi S, Tanabe M et al. Detection of a circulating tumor-associated antigen with a murine monoclonal antibody, LISA 101, selected by reversed indirect enzyme-linked immunosorbent assay. Cancer Res 1989; 49: 341219.
  • 18
    Hamada H, Kohno N, Hiwada K. A new serum tumor marker, CAM 123-6, highly specific to pulmonary adenocarcinoma. Jpn J Cancer Res 1994; 85: 21119.
  • 19
    Kohno N, Inoue Y, Hamada H et al. Differences in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer Suppl 1994; 8: 813.
  • 20
    Wesseling J, Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995; 129: 25565.
  • 21
    Kondo K, Kohno N, Yokoyama A, Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res 1998; 58: 201419.
  • 22
    Burchell J, Gendler S, Taylor-Papadimitriou J et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987; 47: 547682.
  • 23
    Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003; 94: 57581.
  • 24
    Hinoda Y, Sasaki S, Ishida T, Imai K. Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 2004; 95: 6215.
  • 25
    Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002; 195: 12533.
  • 26
    Croix BS, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27KIP1. J Cell Biol 1998; 142: 55771.
  • 27
    Hayashi T, Takahashi T, Motoya S et al. MUC1 mucin core protein binds to the domain 1 of ICAM-1. Digestion 2001; 63: S8792.
  • 28
    Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004; 95: 37784.
  • 29
    Komatsu M, Yee L, Carraway KL. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res 1999; 59: 222936.
  • 30
    Ikeda H, Chamoto K, Tsuji T et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004; 95: 697703.
  • 31
    Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 2005; 174: 570612.
  • 32
    Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983; 221: 8657.
  • 33
    Kawakami Y, Fujita T, Matsuzaki Y et al. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 2004; 95: 78491.
  • 34
    Von Mensdorff-Pouilly S, Petrakou E, Kenemans P et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000; 86: 70212.
  • 35
    KaranikasV, Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100: 278392.
  • 36
    Nicholson S, Bomphray CC, Thomas H et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother 2004; 53: 80916.
  • 37
    Bono JS, Rha SY, Stephenson J et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol 2004; 15: 182533.